News
Dr. Rich Keefe Co-authors Article on a Novel Digital Intervention for ADHD in The Lancet Digital Health
The Lancet Digital Health published the article “A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD); a randomized controlled trial” on Monday, February 24. VeraSci CEO Dr. Rich Keefe was a co-author on this article. The article...
VeraSci Global Language Solutions Are Now ISO Certified
True to the source. True to the science. High quality translations for life science companies at a world class standard. VeraSci Global Language Solutions, the translation and cultural adaptation arm of VeraSci, an innovative scientific services and technology...
VeraSci’s Innovation Lab Launches Wearable Technology Validation Study
Testing Industry-Grade Wearable Devices for Real-Time Functional Assessment. VeraSci’s Innovation Lab led by Dr. Alexandra Atkins has begun evaluating the ease of use, sensitivity, and reliability of two industry-grade wearable devices for the real-time capture of...
Moving the Conversation from Cost to Value: VeraSci Offers New Approach to HEOR and HTA Consulting Led by Dr. Luca Pani
VeraSci, a leading provider of innovative scientific and technology services, announces the addition of a new service offering, Value Consulting, a HEOR and HTA consulting service line, addressing the emerging need to demonstrate the pharmacoeconomic value of novel...
VeraSci Receives FDA Grant to Support Qualification of the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)
VeraSci, a leading provider of innovative scientific and biotechnology services, announced today that they have received an FDA grant to conduct further research on the VRFCAT, their proprietary functional capacity assessment. The VRFCAT has recently been accepted...
VeraSci’s Virtual Reality Functional Capacity Assessment Tool (VRFCAT) Accepted into the FDA’s Clinical Outcome Assessment (COA) Qualification Program
VeraSci, a leading provider of innovative scientific and biotechnology services, announced today that their proprietary functional capacity assessment, the VRFCAT has officially been accepted into the FDA’s COA Qualification Program.
VeraSci Welcomes William P. Horan, PhD as VP of Clinical Science
VeraSci, a leading provider of innovative scientific and technology services, announced today that William P. Horan, PhD will join the company as Vice President of Clinical Science. In this role, Dr. Horan will use his expertise in cognition, clinical neuroscience,...
Leading Provider of Innovative Scientific and Technology Services Welcomes Mark Skeen, MD as Senior Medical Scientist
VeraSci recently welcomed Mark Skeen, MD as Senior Medical Scientist. In this role Dr. Skeen will provide disease state expertise for a broad range of neurologic diseases as well as the perspective of the clinician conducting clinical trials. As part of his role at...
Significant Enhancements Announced for Pathway, VeraSci’s Proprietary eCOA Platform
Significant Enhancements Announced for Pathway, VeraSci’s Proprietary eCOA Platform Integrating Clinical, Cognitive and Functional Assessments onto one device. Durham, NC—December 6, 2018—VeraSci, a global clinical technology and research services company,...
NeuroCog Trials is now VeraSci
Durham, NC—October 12, 2018— NeuroCog Trials announced today that they are changing their name to VeraSci and have rebranded all of their materials and website to better represent their current position as comprehensive collaborative partners in scientific discovery....